Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056604 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2ATMEPHX2MEN1KMT2A | |
| SCHEMBL1717843 | 0.83 | POLB (0.38) | KMT2ATSHRALDH1A1DGAT1LMNA | |
| SCHEMBL8790493 | 0.82 | BRD4 (0.38) | BRD4LTA4HDRD2DRD4SMN1; SMN2 | |
| SCHEMBL6259294 | 0.79 | AKR1C3 (0.40) | ATMEPHX1 | |
| SCHEMBL2864044 | 0.79 | BRD4 (0.50) | BRD4LTA4HSMN1; SMN2 | |
| SCHEMBL1717888 | 0.79 | ITGB3 (0.39) | — | |
| SCHEMBL23277738 | 0.79 | MAP4K4 (0.39) | EPHX2KMT2AEPHX1LMNA | |
| SCHEMBL26647720 | 0.78 | BRD4 (0.50) | BRD4LTA4HSMN1; SMN2EPHX2KMT2A | |
| SCHEMBL24197361 | 0.78 | BRD4 (0.50) | BRD4LTA4HSMN1; SMN2EPHX2KMT2A | |
| SCHEMBL2036054 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284505-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | Pfizer Ireland Pharmaceuticals (IE) | 2023-12-06 | — | — | EP | disclosed |
| EP-3303334-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196840-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-2448942-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | Schering Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002887-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | WO | disclosed |